Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Regenxbio Inc (NASDAQ: RGNX) closed at $7.85 in the last session, down -0.63% from day before closing price of $7.9. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 0.64 million shares were traded. RGNX stock price reached its highest trading level at $8.12 during the session, while it also had its lowest trading level at $7.72.
Ratios:
We take a closer look at RGNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.13. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 12 ’25 when Mills Kenneth T. sold 20,602 shares for $7.91 per share. The transaction valued at 163,046 led to the insider holds 475,103 shares of the business.
KENNETH MILLS bought 20,602 shares of RGNX for $154,927 on May 12 ’25. On Dec 30 ’24, another insider, VITTAL VASISTA, who serves as the Officer of the company, bought 20,041 shares for $7.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 396536480 and an Enterprise Value of 344929600. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.55 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 2.214 whereas that against EBITDA is -2.319.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.17, which has changed by -0.34309626 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $13.48, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is -10.78%, while the 200-Day Moving Average is calculated to be -5.76%.
Shares Statistics:
According to the various share statistics, RGNX traded on average about 942.23K shares per day over the past 3-months and 673560 shares per day over the past 10 days. A total of 50.39M shares are outstanding, with a floating share count of 45.78M. Insiders hold about 9.38% of the company’s shares, while institutions hold 84.75% stake in the company. Shares short for RGNX as of 1752537600 were 6179816 with a Short Ratio of 6.56, compared to 1749772800 on 5512274. Therefore, it implies a Short% of Shares Outstanding of 6179816 and a Short% of Float of 14.899999.
Earnings Estimates
Its stock is currently analyzed by 7.0 different market analysts. The consensus estimate for the next quarter is $0.8, with high estimates of $3.31 and low estimates of -$1.47.
Analysts are recommending an EPS of between $0.92 and -$4.09 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$2.47, with 7.0 analysts recommending between $0.91 and -$5.7.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $24.98M. It ranges from a high estimate of $45.84M to a low estimate of $11.66M. As of the current estimate, Regenxbio Inc’s year-ago sales were $24.2MFor the next quarter, 10 analysts are estimating revenue of $108.56M. There is a high estimate of $263.97M for the next quarter, whereas the lowest estimate is $20M.
A total of 10 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $345.21M, while the lowest revenue estimate was $151.4M, resulting in an average revenue estimate of $238.04M. In the same quarter a year ago, actual revenue was $83.33MBased on 11 analysts’ estimates, the company’s revenue will be $257.38M in the next fiscal year. The high estimate is $436.92M and the low estimate is $139.83M.
